We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNovaBridge Biosciences

NovaBridge Biosciences

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.8418 USD -0.02 ( 2.23%)
Last update at 2026-11-12T15:40:00Z
VOLUME
302179
Market Cap
183.88M

Momentum Score

…

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.82
Low
0.90
High
52 Week Price Range
1.46
Low
6.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.86
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-59.10%
Net Debt
-29.67M
ROCE
-40.35%
Diluted EPS TTM
-0.68

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -12.63M -362.73M -1465.69M -973.17M -2332.04M
Minority interest 42.07M 0.00M 0.00M - -
Net income -6.61M -162.26M -1465.69M -967.52M -2331.54M
Selling general administrative 4.48M 216.46M 63.91M 199.88M 899.94M
Gross profit -0.86M - 4.49M -10.70M 41.59M
Reconciled depreciation 0.86M 0.98M 1.06M 1.42M 5.36M
Ebit -13.48M -375.36M -347.62M -366.08M -2071.31M
Ebitda -13.35M -373.45M -344.25M -356.38M -2057.53M
Depreciation and amortization 0.12M 1.91M 3.37M 9.70M 13.78M
Operating income -13.48M -375.36M -511.16M -366.08M -2071.31M
Other operating expenses 13.48M 375.36M 515.65M 355.38M 2159.33M
Interest expense - - 0.10M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.10M -0.49M
Interest income 7.61M 7.49M 9.29M 4.95M 3.35M
Net interest income 7.61M 7.49M 9.29M 4.95M 3.35M
Income tax expense - - -1258.93M -5.65M -0.49M
Total revenue 0.00M 0.00M 4.49M -10.70M 88.03M
Total operating expenses 13.48M 375.36M 515.65M 355.38M 2112.90M
Cost of revenue 0.86M - 0.00M 27.24M 46.43M
Total other income expense net 0.85M 12.63M -954.53M -607.09M -260.73M
Net income from continuing ops -88.34M -49.70M -82.22M -141.20M -365.78M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 37.24M 1552.31M 368.92M 4073.66M 878.74M
Intangible assets - - 16.66M 118.89M 18.77M
Other current assets 0.70M 24.05M 16.35M 252.51M 13.99M
Total liab 4.23M 84.08M 126.34M 1065.34M 163.42M
Total stockholder equity 33.02M 1468.23M 242.58M 3008.33M 715.33M
Other current liab 3.72M 55.75M 57.52M 651.33M 92.71M
Common stock 0.00M 0.14M 0.02M 0.13M 0.02M
Capital stock 0.03M 0.02M 0.02M 0.02M 0.02M
Retained earnings -190.47M -9386.54M -1263.81M -6766.65M -683.21M
Good will - - 0.00M 162.57M 25.51M
Other assets -21751999782.48M - - - -
Cash 30.11M 498.24M 291.51M 3214.01M 552.80M
Total current liabilities 3.84M 61.70M 58.14M 659.74M 97.90M
Current deferred revenue - 0.77M 1.58M 2.19M 0.37M
Net debt -29.67M -469.90M -287.62M -3175.72M -535.16M
Short term debt 0.13M 5.96M 0.63M 6.22M 4.81M
Short long term debt - - 4.23M 2.75M -
Short long term debt total 0.44M 28.33M 3.89M 38.29M 17.64M
Other stockholder equity 217.54M 10610.97M 1466.60M 9558.13M 1427.77M
Total current assets 31.10M 1289.65M 329.91M 3626.48M 750.18M
Long term investments 37.24M 30.82M 0.00M 4.47M 55.24M
Short term investments 0.03M 767.36M 20.22M 235.43M 118.16M
Net receivables 0.26M 8.55M 1.83M 4.81M 60.95M
Long term debt - - 8.31M - -
Inventory - - 28.95M -80.28M 4.27M
Accumulated other comprehensive income 5.94M 243.66M 39.77M 216.72M -29.26M
Non currrent assets other 0.40M 9.96M 33.46M 10.91M 4.18M
Non current assets total 6.15M 262.66M 39.01M 447.19M 128.56M
Capital lease obligations 3.07M 3.88M 3.89M 8.12M 17.64M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 104.92M -136.01M -15.16M -5.18M -114.09M
Total cashflows from investing activities 104.97M -992.42M -107.63M 458.38M -727.21M
Net borrowings - - 9.86M 2.75M 0.00M
Total cash from financing activities 57.73M -2.44M -8.25M 42.36M 593.92M
Net income -88.34M -362.72M -208.18M -2507.32M -2331.54M
Change in cash 142.37M -1706.19M -151.58M -212.86M -1235.15M
Begin period cash flow 68.26M 2204.27M 462.92M 3523.63M 4758.78M
End period cash flow 210.63M 498.07M 311.34M 3310.77M 3523.63M
Total cash from operating activities -20.60M -384.29M -72.85M -1102.81M -973.09M
Issuance of capital stock 61.71M 0.00M 0.00M 0.00M 0.00M
Depreciation 0.86M 7.14M 1.06M 63.82M 34.14M
Other cashflows from investing activities 0.05M 0.45M -107.47M 0.03M -
Change to inventory - - 0.00M 27.24M -27.24M
Change to account receivables - 0.00M 0.00M 33.08M 97.42M
Sale purchase of stock 0.00M -2.45M -8.66M -3.08M 0.00M
Other cashflows from financing activities -4.19M - 0.41M 42.69M 593.92M
Capital expenditures 0.01M 0.35M 0.16M 45.83M 29.93M
Change in working capital 17.07M -20.52M -37.20M 552.06M 394.52M
Stock based compensation 5.97M -14.23M 10.26M 357.15M 608.61M
Other non cash items 43.84M 5.90M 161.20M 431.48M 321.18M
Free cash flow -20.60M -384.77M -73.02M -1148.63M -1003.02M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NBP
NovaBridge Biosciences		 -0.02
2.23%		 0.84 - 2.68 25.39 0.93 0.14
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

2440 Research Boulevard, Rockville, MD, United States, 20850

240 745 6330

https://novabridge.com

30

Name Title Year Born
Mr. Wei Fu Executive Chairman 1982
Mr. Ming Lei Chief Financial Officer 1997
Mr. Sean Wuxiong Cao M.B.A., Ph.D. Chief Business Development Officer & Director 1967
Dr. Srishti Gupta M.D. CEO & Director 1976
Mr. Mark Hagler President & Chief Commercial Officer NA
Mr. Tyler Ehler Senior Director of Investor Relations NA
Ms. Liwei Lin General Counsel & Board Secretary 1988
Dr. Cong Xu M.D., Ph.D. Senior VP and Head of R&D Center of Excellence 1985
Dr. Phillip Dennis M.D., Ph.D. Chief Medical Officer 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…